INS and diabetes mellitus: In response to the increased spending and limited affordability of this expensive but essential drug for diabetes care, the Centers for Medicare and Medicaid Services (CMS) recently announced a voluntary model under which some Part D plans and pharmaceutical manufacturers would come together to lower Medicare beneficiaries’ out-of-pocket cost for insulin to $35 per month, starting January 1, 2021 [17].